Kypha Raises $2.1 Million in Debt Offering

Kypha, a Serra Capital II company, was featured by the St. Louis Business Journal on November 13. Kypha is an early-stage company developing new products to improve the way inflammation and immune activity is monitored and treated.

Kypha has raised $2.1 million in a debt offering, according to a filing with the Securities and Exchange Commission. The article also listed Serra Ventures as an investor.